BTIG launched coverage of Definitive Healthcare (NASDAQ:DH) with a “buy” rating and $7 target price. The stock closed at $4.44 on September 16. Definitive Healthcare is one of the industry’s most comprehensive...
BTIG reinitiated its coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and $27 price target. The stock closed at $20.65 on July 18. BTIG previously covered the legacy Orthofix from 2017-to-2021 and the...
BTIG initiated coverage of Beyond Air (NASDAQ:XAIR) with a “buy” rating and $15 price target. The stock closed at $5.73 on June 14. Beyond Air is a medical device company that has developed a technology to turn room air...
BTIG launched coverage of Coya Therapeutics (NASDAQ:COYA) with a “buy” rating and a $15 price target. The stock closed at $5.76 on May 17. Analyst Thomas Shrader, Ph.D., writes that his price target is based on “our...
BTIG downgraded Babylon Health (NASDAQ:BBLN) to “sell” from “neutral” with a price target of zero, reflecting concerns around earnings, cash flow and cash needs, and the structure of a possible go-private transaction...
BTIG downgraded CareDx (NASDAQ:CDNA) to “neutral” from “buy” and removed its price target. The stock closed at $8.59 on May 10. CareDx is a market leader in blood-based testing for both heart and kidney transplant...
BTIG launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $15 price target. The stock closed at $9.11 on March 8. Analyst Julian Harrison writes that the company’s seladelpar is well...
BTIG initiated coverage of Moonlake Immunotherapeutics (NASDAQ:MLTX) with a “buy” rating and $36 price target. The stock closed at $23.70 on March 8. “We see Moonlake’s sonelokimab (SLK) well-positioned to emerge as the...
BTIG initiated coverage of Sophia Genetics (NASDAQ:SOPH) with a “buy” rating and $6 price target. The stock price closed at $2.06 on Dec. 30. Sophia is a rapidly growing, global healthcare technology company that sells...
BTIG analyst Mark Massaro assumed coverage of Bionano Genomics (NASDAQ:BNGO) with a “buy” rating and price target of $3.50. The stock closed at $2.16 on Dec. 9. Bionano provides optical genome mapping technology tools...